文献速递脑血管病

美国17年间颈动脉血运重建术式利用趋势

Trends in the Utilization of Different Carotid Revascularization Modalities in the United States Over a 17-Year Period.
PubMed 文献 · Neurology · 2025-09-19

该研究基于2006-2022年全国住院样本及四州数据库,分析美国颈动脉血运重建术式的利用趋势。结果显示,颈动脉支架置入术(CAS)占比从14.3%升至29.0%,而颈动脉内膜切除术(CEA)利用率下降;每10万人口血运重建率整体下降但2015年后趋于平稳。仅25.7%的手术用于症状性疾病。

要点

  • CAS占比从14.3%增至29.0%,2022年经颈动脉血运重建占9.1%。
  • CEA利用率2006-2022年下降(APC -5.5%),CAS先降后升(2016-2022年APC 12.0%)。
  • 仅25.7%的血运重建用于症状性疾病,女性中75.3%住院为无症状。

核心结论

  • 过去十年CAS使用在各年龄和性别组中增加,目前占美国颈动脉血运重建的25%以上,尽管在部分人群(如>70岁和 asymptomatic 患者)中获益不确定。

研究设计与样本

  • 序列横断面研究使用2006-2022年全国住院样本,以及佛罗里达(2005-2021)、佐治亚(2010-2020)、马里兰(2012-2021)和纽约(2005-2020)的州急诊和住院数据库。
  • 通过ICD代码识别颈动脉血运重建病例,计算年龄和性别特异性比例及每10万人口利用率,采用Joinpoint回归估计年化百分比变化(APC)。

主要发现

  • 共1,779,948例加权血运重建,平均年龄71.0岁,40.9%为女性。
  • CAS占17.2%,比例从14.3%增至29.0%;2022年经颈动脉血运重建占9.1%。
  • 每10万人口血运重建率下降(APC -3.9%,95% CI -4.1%至-3.3%),但2015年后趋于平稳。
  • CEA利用率2006-2022年下降(APC -5.5%,95% CI -5.9%至-5.1%);CAS 2006-2016年下降(APC -3.2%,95% CI -4.6%至-2.1%),2016-2022年上升(APC 12.0%,95% CI 10.1%-14.1%)。
  • 四州中仅25.7%的血运重建用于症状性疾病,女性中75.3%的住院为无症状性疾病。

临床怎么用

  • 临床医生应了解CAS使用增加的趋势,尤其在老年和无症状患者中需谨慎评估获益与风险。
  • 在女性患者中,多数血运重建用于无症状性疾病,应加强症状评估和个体化决策。

局限性

  • 研究为观察性设计,使用行政数据库,可能存在编码错误和未测量混杂因素。
  • 症状状态定义基于血运重建前6个月的住院记录,可能不准确。
  • 结果主要反映CMS政策变化前的趋势,可能不适用于当前实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In October 2023, the Centers for Medicare & Medicaid Services (CMS) in the United States expanded coverage for carotid artery stenting (CAS) to include non-high-risk patients with carotid disease. The aim of this study was to provide a 17-year snapshot of trends in carotid revascularization practices in the United States before this CMS policy change went into effect. METHODS: We conducted a serial cross-sectional study using the 2006-2022 National Inpatient Sample and a retrospective cohort study using the State Emergency and Inpatient Databases of Florida (2005-2021), Georgia (2010-2020), Maryland (2012-2021), and New York (2005-2020). Cases of carotid revascularizations in these databases were identified using International Classification of Diseases codes. We calculated age-specific and sex-specific proportions of revascularizations for CAS and combined annual CAS/carotid endarterectomy (CEA) counts with census data to determine utilization rates per 100,000 population. Joinpoint regression estimated annualized percentage change (APC) over time. Hospitalizations in the 6 months preceding revascularization defined symptomatic vs asymptomatic cases and characterized the subset with symptomatic stenosis. RESULTS: Of 1,779,948 weighted revascularizations, the mean patient age was 71.0 years and 40.9% were performed in women. 17.2% of procedures were CAS, and this proportion more than doubled from 14.3% to 29.0%. Transcarotid artery revascularization accounted for 9.1% in 2022. The CAS proportion increased across age groups, including in those aged older than 70 years and in women, even after excluding mechanical thrombectomy admission. Carotid revascularization usage per 100,000 population declined (APC -3.9%, 95% CI -4.1% to -3.3%) but plateaued after 2015. Although CEA utilization declined from 2006 to 2022 (APC -5.5%, 95% CI -5.9% to -5.1%), CAS use declined from 2006 to 2016 (APC -3.2%, 95% CI -4.6% to -2.1%) but increased from 2016 to 2022 (APC 12.0%, 95% CI 10.1%-14.1%). Only 25.7% of revascularizations in the 4 states were performed for symptomatic disease, with 75.3% of hospitalizations in women for asymptomatic disease. DISCUSSION: Despite uncertain benefit in selected age and sex groups, including those older than 70 years and with asymptomatic carotid disease, CAS use increased across groups over the past decade and now accounts for >25% of carotid revascularizations in the United States.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Otite FO, Morris NA, Sabra A, et al. Trends in the Utilization of Different Carotid Revascularization Modalities in the United States Over a 17-Year Period. Neurology. 2025. PMID: 40971741. doi:10.1212/WNL.0000000000214104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。